Richard G Gorlick
Overview
Explore the profile of Richard G Gorlick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Truong D, Weistuch C, Murgas K, Admane P, King B, Chauviere Lee J, et al.
Clin Cancer Res
. 2024 May;
30(15):3259-3272.
PMID: 38775859
Purpose: The genetic intratumoral heterogeneity observed in human osteosarcomas poses challenges for drug development and the study of cell fate, plasticity, and differentiation, which are processes linked to tumor grade,...
2.
Dubois S, Krailo M, Glade-Bender J, Buxton A, Laack N, Randall R, et al.
J Clin Oncol
. 2023 Jan;
41(11):2098-2107.
PMID: 36669140
Purpose: Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to...
3.
Ahmed S, Witten B, Harmsen W, Rose P, Krailo M, Marcus K, et al.
Int J Radiat Oncol Biol Phys
. 2022 Oct;
115(2):337-346.
PMID: 36302496
Purpose: To identify potential clinical prognostic factors associated with a higher risk of local recurrence in patients with localized pelvic Ewing sarcoma treated with radiation therapy. Methods And Materials: Data...
4.
Hingorani P, Krailo M, Buxton A, Hutson P, Sondel P, Diccianni M, et al.
Eur J Cancer
. 2022 Jul;
172:264-275.
PMID: 35809374
Purpose: Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed in human osteosarcoma tumours and cell lines. This study evaluated the disease control rate (DCR) in patients...
5.
Collier 3rd A, Krailo M, Dang H, Dubois S, Hawkins D, Bernstein M, et al.
Pediatr Blood Cancer
. 2021 Sep;
68(12):e29333.
PMID: 34496122
SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients...
6.
Dubois S, Krailo M, Buxton A, Lessnick S, Teot L, Rakheja D, et al.
Arch Pathol Lab Med
. 2021 Mar;
145(12):1564-1568.
PMID: 33769463
Context.—: Molecular diagnostics play an increasing role in the diagnosis of Ewing sarcoma. The type of molecular testing used in clinical practice has been poorly described. Objective.—: To describe patterns...
7.
Currier A, Kolb E, Gorlick R, Roth M, Gopalakrishnan V, Sampson V
Sci Rep
. 2019 Apr;
9(1):6161.
PMID: 30992462
The p27/kip1 (p27) tumor suppressor inhibits cyclin/cyclin-dependent kinase (CDK) complexes and halts cell cycle progression. p27 further regulates invasion and migration in cancer cells, suggesting p27 also functions as an...
8.
Zhu C, Olson K, Roth M, Geller D, Gorlick R, Gill J, et al.
J Surg Oncol
. 2017 Oct;
117(3):417-424.
PMID: 29044582
Background: Curative therapy for ES requires both chemotherapy and local control of primary tumor. There is no universally accepted standard approach to local control modalities. This survey was conducted to...
9.
Ahmed S, Randall R, Dubois S, Harmsen W, Krailo M, Marcus K, et al.
Int J Radiat Oncol Biol Phys
. 2017 Oct;
99(5):1286-1294.
PMID: 28964585
Purpose: To identify clinical and treatment variables associated with a higher risk of local failure in Ewing sarcoma patients treated on recent Children's Oncology Group protocols. Methods And Materials: Data...
10.
Davis L, Janeway K, Weiss A, Chen Y, Scharschmidt T, Krailo M, et al.
Cancer
. 2017 May;
123(18):3434-3440.
PMID: 28493547
More than half of all sarcomas occur in adolescents and young adults (AYAs) aged 15 to 39 years. After the publication of the AYA series in the April 1, 2016...